MedTrace Logo

Study of 3D189 in Patients With Hematologic Malignancies

NCT05320809 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-05-29

No results posted yet for this study

Summary

To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.

Conditions

Interventions

BIOLOGICAL

3D189

3D189 (200 mcg per peptide x 4 WT1 peptides within the drug product; total weight: 800 mcg) is mixed (1:1 v/v) and emulsified with the adjuvant Montanide, which is then injected subcutaneously to the patient. A maximum of 15 total injections of 3D189 will be administered as follows: 1. Initial immunization induction phase（the first series of 6 injections of 3D189): every 2 weeks (Weeks 0 - 10) followed by a 4-week period of no treatment. 2. Early immune booster phase（the second series of 6 injections of 3D189): every 4 weeks (between Weeks 14 and 34) followed by a 6-week period of no treatment. 3. Late immune booster phase（the third series of 3 injections of 3D189): every 6 weeks (between Weeks 40 and 52).

Sponsors & Collaborators

  • 3D Medicines

    lead INDUSTRY

Principal Investigators

  • jianxiang wang, Ph.D · Institute of Hematology & Blood Diseases Hospital,Chinese Academy of Medical Science & Peking Union Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2026-06-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320809 on ClinicalTrials.gov